Related Experiment Videos
Letterer-Siwe disease: a study of thirteen cases over a 21 - year period
Insights
Letterer-Siwe disease, a rare childhood illness, shows high mortality in Northern Ireland. Early diagnosis and quadruple chemotherapy may improve outcomes for pulmonary complications.
Area of Science:
- Pediatric Oncology
- Hematology
- Rare Diseases
Background:
- Letterer-Siwe disease is a rare, aggressive form of histiocytosis X.
- Understanding its epidemiology and clinical course is crucial for patient management.
Purpose of the Study:
- To analyze the incidence, clinical features, and outcomes of Letterer-Siwe disease in Northern Ireland.
- To evaluate the effectiveness of treatment modalities, particularly for pulmonary involvement.
Main Methods:
- Retrospective review of 13 diagnosed cases over 21 years in Northern Ireland.
- Analysis of patient demographics, age of onset, survival time, morbidity, and mortality.
- Assessment of treatment responses, focusing on pulmonary complications.
Main Results:
- 13 cases diagnosed over 21 years in a population of 1.5 million.
- Average age of onset: 10.5 months; mortality rate: 69%; average survival: 3.3 months.
- Pulmonary complications were the primary cause of death; two cases responded to quadruple chemotherapy.
Conclusions:
- Letterer-Siwe disease has a significant mortality rate in Northern Ireland.
- Pulmonary involvement is a critical factor in survival.
- Prompt treatment, including chemotherapy, may offer survival benefits for specific complications.
Abstract:
In Northern Ireland, with a population of 1.5 million, thirteen cases of Letterer-Siwe disease have been diagnosed over the past 21 years. The average age of onset was 10.5 months. There was a 69% mortality with an average survival time from diagnosis to death of 3.3 months. Four children survived with no morbidity. All deaths were from pulmonary complications, but two cases with pulmonary infiltration responded to treatment with quadruple chemotherapy. There were no familial cases in this study.